Team Starts Trial for ALS Drug Development with iPS Use

By IPS, Medical science

Team Starts Trial for ALS Drug Development with iPS Use

Tokyo, Dec. 3 (Jiji Press)–A Keio University team said Monday that it has started a clinical trial on a candidate for an amyotrophic lateral sclerosis drug found through the use of induced pluripotent stem, or iPS, cells created from cells of ALS patients.

As the disease progresses, sufferers lose their ability to move their muscles. There are about 10,000 ALS patients in Japan.

The team, led by Prof. Hideyuki Okano at the university, created iPS cells from the bloods of ALS patients and transformed them into neurons with the disease.

After adding various compounds used as drugs for other diseases into the neurons, the team found that ropinirole hydrochloride, a drug for Parkinson’s disease, is effective in curbing their death.

JIJI PRESS

https://jen.jiji.com/jc/i?g=eco&k=2018120300009

https://www.google.co.jp/amp/s/www.sankei.com/life/amp/181203/lif1812030004-a.html

More from tokioX :

  1. Keio University: Suppression of ALS progression with ropinirole: Drug discovery with iPS cells
  2. Osaka Univ: Making eye conjunctival cells with iPS: Expectations for drug discovery of dry eye
  3. iPS drug discovery: The world’s first clinical trial of Alzheimer’s disease: 7 hospitals at Kyoto /Mie Univ
  4. COVID-19: Japanese Avegan clinical trial, continued in July: Infected population  shortage
  5. COVID-19: Chugai / Roche, Actemra Phase III study commenced: FDA / a clinical trial with ASPR
  6. Kyoto University: Development of nasal vaccine for dementia: iPS Cell Research Institute
  7. Roche – initiates Phase III clinical trial of Actemra/RoActemra with COVID-19 pneumonia